Nephrology, Dialysis and Transplantation Unit, Department of Precision and Regenerative Medicine and Ionian Area (DiMePRe-J), University of Bari "Aldo Moro," Bari, Italy.
Centre for Medical Sciences - CISMed, University of Trento, Trento, Italy.
Semin Respir Crit Care Med. 2024 Aug;45(4):491-502. doi: 10.1055/s-0044-1789240. Epub 2024 Aug 29.
Sepsis, the dysregulated immune response of the host to infections, leads to numerous complications, including multiple organ dysfunction with sepsis-associated acute kidney injury (SA-AKI) being a frequent complication associated with increased risk of mortality and the progression toward chronic kidney disease (CKD). Several mechanisms have been widely investigated in understanding the complex pathophysiology of SA-AKI, including hemodynamic alterations, inflammation, oxidative stress, and direct cellular injury driven by pathogens or cell-derived products (pathogen-associated molecular patterns and damage-associated molecular patterns). Despite advancements in the management of septic patients, the prognosis of SA-AKI patients remains significantly poor and is associated with high in-hospital mortality and adverse long-term outcomes. Therefore, recent research has focused on the early identification of specific SA-AKI endotypes and subphenotypes through epigenetic analysis and the use of potential biomarkers, either alone or in combination with clinical data, to improve prognosis. Epigenetic regulation, such as DNA methylation, histone modifications, and noncoding RNA modulation, is crucial in modulating gene expression in response to stress and renal injury in SA-AKI. At the same time, these modifications are dynamic and reversible processes that can alter gene expression in several pathways implicated in the context of SA-AKI, including inflammation, immune response, and tolerance status. In addition, specific epigenetic modifications may exacerbate renal damage by causing persistent inflammation or cellular metabolic reprogramming, leading to progression toward CKD. This review aims to provide a comprehensive understanding of the epigenetic characteristics that define SA-AKI, also exploring targeted therapies that can improve patient outcomes and limit the chronic progression of this syndrome.
脓毒症是宿主对感染的失调免疫反应,导致许多并发症,包括多器官功能障碍,其中脓毒症相关急性肾损伤(SA-AKI)是一种常见的并发症,与死亡率增加和向慢性肾脏病(CKD)进展的风险增加有关。已经广泛研究了几种机制来理解 SA-AKI 的复杂病理生理学,包括血流动力学改变、炎症、氧化应激以及病原体或细胞衍生产物(病原体相关分子模式和损伤相关分子模式)引起的直接细胞损伤。尽管在治疗脓毒症患者方面取得了进展,但 SA-AKI 患者的预后仍然很差,与院内死亡率高和不良的长期结局相关。因此,最近的研究集中在通过表观遗传分析和使用潜在生物标志物(单独或与临床数据结合)来早期识别特定的 SA-AKI 内表型和亚表型,以改善预后。表观遗传调节,如 DNA 甲基化、组蛋白修饰和非编码 RNA 调节,在调节 SA-AKI 中应激和肾损伤时的基因表达中至关重要。同时,这些修饰是动态和可逆的过程,可以改变涉及 SA-AKI 背景的几个途径中的基因表达,包括炎症、免疫反应和耐受状态。此外,特定的表观遗传修饰可能通过引起持续的炎症或细胞代谢重编程来加剧肾损伤,导致 CKD 的进展。本综述旨在全面了解定义 SA-AKI 的表观遗传特征,同时探索可以改善患者预后和限制该综合征慢性进展的靶向治疗。